Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 3/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL30467728 | 0.95 | DHFR (0.31) | DHFRCA12CA1CA2CA9 | |
| Formic Acid SCHEMBL25247744 | 0.95 | DHFR (0.31) | DHFRCA12CA1CA2CA9 | |
| SCHEMBL30452821 | 0.92 | PDE4B (0.37) | DHFRCA12CA1CA2CA9 | |
| SCHEMBL24252507 | 0.92 | PDE4B (0.37) | DHFRCA12CA1CA2CA9 | |
| SCHEMBL24252647 | 0.85 | CA12 (0.40) | CA12CA1CA2CA9 | |
| SCHEMBL26771125 | 0.85 | DHFR (0.33) | DHFRMAP4K4 | |
| Formic Acid SCHEMBL30467643 | 0.80 | CA12 (0.36) | CA12CA1CA2CA9 | |
| Formic Acid SCHEMBL25212277 | 0.80 | CA12 (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL24252652 | 0.79 | PDE10A (0.40) | DHFR | |
| SCHEMBL26777173 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | DHFR 1380/4885CA12 3345/4885CA1 3241/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | DHFR 1380/4885CA12 3345/4885CA1 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.